SEARCH

SEARCH BY CITATION

References

  • Baccarini, M. (2005). Second nature: biological functions of the Raf-1 “kinase”. FEBS Lett. 579, 32713277.
  • Bild, A.H., Yao, G., Chang, J.T. et al. (2006). Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439, 353357.
  • Böhm, M., Moellmann, G., Cheng, E., Alvarez-Franco, M., Wagner, S., Sassone-Corsi, P., and Halaban, R. (1995). Identification of p90RSK as the probable CREB-Ser133 kinase in human melanocytes. Cell Growth Differ. 6, 291302.
  • Craig, E.A., Stevens, M.V., Vaillancourt, R.R., and Camenisch, T.D. (2008). MAP3Ks as central regulators of cell fate during development. Dev. Dyn. 237, 31023114.
  • Curtin, J.A., Busam, K., Pinkel, D., and Bastian, B.C. (2006). Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 24, 43404346.
  • Dent, P., Reardon, D.B., Morrison, D.K., and Sturgill, T.W. (1995). Regulation of Raf-1 and Raf-1 mutants by Ras-dependent and Ras-independent mechanisms in vitro. Mol. Cell. Biol. 15, 41254135.
  • Dhomen, N., and Marais, R. (2009). BRAF signaling and targeted therapies in melanoma. Hematol. Oncol. Clin. North Am. 23, 529545. ix.
  • Emery, I.F., Battelli, C., Auclair, P.L., Carrier, K., and Hayes, D.M. (2009). Response to gefitinib and erlotinib in non-small cell lung cancer: a retrospective study. BMC Cancer 9, 333.
  • Flaherty, K., Puzanov, I., Sosman, J., Kim, K., Ribas, A., Mcarthur, G., Lee, R.J., Grippo, J.F., Nolop, K., and Chapman, P. (2009). Phase I study of PLX4032: proof of concept for V600EBRAF mutation as a therapeutic target in human cancer. J. Clin. Oncol. 27, 15s. 27.
  • Forbes, S.A., Bhamra, G., Bamford, S., Dawson, E., Kok, C., Clements, J., Menzies, A., Teague, J.W., Futreal, P.A., and Stratton, M.R. (2008). The catalogue of somatic mutations in cancer (COSMIC). Curr. Protoc. Hum. Genet. Chapter 10, Unit 10.11.
  • Garnett, M.J., Rana, S., Paterson, H., Barford, D., and Marais, R. (2005). Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol. Cell 20, 963969.
  • Halaban, R., Krauthammer, M., Pelizzola, M. et al. (2009). Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications. PLoS ONE 4, e4563.
  • Hall-Jackson, C.A., Eyers, P.A., Cohen, P., Goedert, M., Boyle, F.T., Hewitt, N., Plant, H., and Hedge, P. (1999). Paradoxical activation of Raf by a novel Raf inhibitor. Chem. Biol. 6, 559568.
  • Hatzivassiliou, G., Song, K., Yen, I. et al. (2010). RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. doi: 10.1038/nature08833.
  • Heidorn, S.J., Milagre, C., Whittaker, S. et al. (2010). Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209211.
  • Hodi, F.S., Friedlander, P., Corless, C.L. et al. (2008). Major response to imatinib mesylate in KIT-mutated melanoma. J. Clin. Oncol. 26, 20462051.
  • Hoek, K., Rimm, D.L., Williams, K.R. et al. (2004). Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res. 64, 52705282.
  • Jiang, X., Zhou, J., Yuen, N.K., Corless, C.L., Heinrich, M.C., Fletcher, J.A., Demetri, G.D., Widlund, H.R., Fisher, D.E., and Hodi, F.S. (2008). Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin. Cancer Res. 14, 77267732.
  • King, A.J., Patrick, D.R., Batorsky, R.S. et al. (2006). Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res. 66, 1110011105.
  • Laird, A.D., Morrison, D.K., and Shalloway, D. (1999). Characterization of Raf-1 activation in mitosis. J. Biol. Chem. 274, 44304439.
  • Lu, Z., Xu, S., Joazeiro, C., Cobb, M.H., and Hunter, T. (2002). The PHD domain of MEKK1 acts as an E3 ubiquitin ligase and mediates ubiquitination and degradation of ERK1/2. Mol. Cell 9, 945956.
  • Mitra, S.K., Hanson, D.A., and Schlaepfer, D.D. (2005). Focal adhesion kinase: in command and control of cell motility. Nat. Rev. Mol. Cell Biol. 6, 5668.
  • Rajakulendran, T., Sahmi, M., Lefrancois, M., Sicheri, F., and Therrien, M. (2009). A dimerization-dependent mechanism drives RAF catalytic activation. Nature 2, 2.
  • Rushworth, L.K., Hindley, A.D., O’neill, E., and Kolch, W. (2006). Regulation and role of Raf-1/B-Raf heterodimerization. Mol. Cell. Biol. 26, 22622272.
  • Sala, E., Mologni, L., Truffa, S., Gaetano, C., Bollag, G.E., and Gambacorti-Passerini, C. (2008). BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol. Cancer Res. 6, 751759.
  • Sharma, S.V., and Settleman, J. (2007). Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 21, 32143231.
  • Smalley, K.S., Nathanson, K.L., and Flaherty, K.T. (2009). Genetic subgrouping of melanoma reveals new opportunities for targeted therapy. Cancer Res. 69, 32413244.
  • Tsai, J., Lee, J.T., Wang, W. et al. (2008). Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. U S A 105, 30413046.
  • Weinstein, I.B., and Joe, A. (2008). Oncogene addiction. Cancer Res. 68, 30773080; discussion 3080.